Skip to main
LCTX
LCTX logo

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics Inc. is advancing its innovative ReSonance program, which focuses on developing auditory neuronal cell transplants to enhance cochlear implant outcomes for patients with severe-to-profound hearing loss, highlighting its progress in addressing significant unmet medical needs. The company has successfully reached key preclinical stages of this program with minimal incremental investment, showcasing its efficient use of resources and strategic development. Additionally, a financial commitment of up to $12 million from William Demant Invest provides crucial funding that supports the ongoing development of Lineage’s therapeutic candidates and strengthens its financial position.

Bears say

Lineage Cell Therapeutics Inc has faced challenges due to the clinical uncertainties associated with its product pipeline, particularly the reliance on multiple unproven therapies, which increases the risk profile for investors. Financially, the company has reported limited revenue generation, resulting in a reliance on external financing to support ongoing research and development efforts. Additionally, the potential for lengthy regulatory approval processes further compounds the risk of delayed commercialization and revenue realization for its key product candidates.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.